SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-027534
Filing Date
2021-05-13
Accepted
2021-05-13 16:07:04
Documents
57
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q - MARCH 31, 2021 alna-10q_20210331.htm 10-Q 1862984
2 EX-31.1 alna-ex311_6.htm EX-31.1 16661
3 EX-31.2 alna-ex312_8.htm EX-31.2 16697
4 EX-32.1 alna-ex321_7.htm EX-32.1 10192
  Complete submission text file 0001564590-21-027534.txt   5099091

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT alna-20210331.xml EX-101.INS 772856
6 XBRL TAXONOMY EXTENSION SCHEMA alna-20210331.xsd EX-101.SCH 39356
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE alna-20210331_cal.xml EX-101.CAL 37068
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE alna-20210331_def.xml EX-101.DEF 149335
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE alna-20210331_lab.xml EX-101.LAB 324925
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alna-20210331_pre.xml EX-101.PRE 259160
Mailing Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462
Business Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462 617-467-4577
Allena Pharmaceuticals, Inc. (Filer) CIK: 0001624658 (see all company filings)

IRS No.: 452729920 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38268 | Film No.: 21919622
SIC: 2836 Biological Products, (No Diagnostic Substances)